{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:32:07Z","timestamp":1773088327526,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.beha.2012.04.008","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T07:27:30Z","timestamp":1337239650000},"page":"175-183","source":"Crossref","is-referenced-by-count":21,"title":["Targeting mTOR in mantle cell lymphoma: Current and future directions"],"prefix":"10.1016","volume":"25","author":[{"given":"Sonali M.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2012.04.008_bib1","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.beha.2012.04.008_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.008_bib3","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","article-title":"Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways","volume":"23","author":"Fernandez","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.008_bib4","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.beha.2012.04.008_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2012.04.008_bib6","doi-asserted-by":"crossref","unstructured":"Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol; 12: 21\u201335.","DOI":"10.1038\/nrm3025"},{"key":"10.1016\/j.beha.2012.04.008_bib7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.beha.2012.04.008_bib8","doi-asserted-by":"crossref","unstructured":"Davies MA. Regulation, role, and targeting of akt in cancer. J Clin Oncol; 29: 4715\u20134717.","DOI":"10.1200\/JCO.2011.37.4751"},{"key":"10.1016\/j.beha.2012.04.008_bib9","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol"},{"key":"10.1016\/j.beha.2012.04.008_bib10","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/MCB.01665-08","article-title":"Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth","volume":"29","author":"Acosta-Jaquez","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.beha.2012.04.008_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20110892","article-title":"Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks","volume":"441","author":"Magnuson","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.beha.2012.04.008_bib12","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/jco.2005.23.16_suppl.3033","article-title":"Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor","volume":"23","author":"Rivera","year":"2005","journal-title":"JCO"},{"key":"10.1016\/j.beha.2012.04.008_bib13","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.008_bib14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2010.01.021","article-title":"Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E","volume":"17","author":"Hsieh","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2012.04.008_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature03205","article-title":"Regulation of cap-dependent translation by eIF4E inhibitory proteins","volume":"433","author":"Richter","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.beha.2012.04.008_bib16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature02369","article-title":"Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy","volume":"428","author":"Wendel","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.beha.2012.04.008_bib17","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1002\/cncr.24506","article-title":"Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine","volume":"115","author":"Inamdar","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2012.04.008_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2012.04.008_bib19","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1182\/blood-2009-10-251082","article-title":"Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K\/Akt\/mTOR-addicted lymphomas","volume":"115","author":"Bhatt","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.008_bib20","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol"},{"key":"10.1016\/j.beha.2012.04.008_bib21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/(SICI)1098-2264(199904)24:4<322::AID-GCC5>3.0.CO;2-9","article-title":"Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas","volume":"24","author":"Butler","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.beha.2012.04.008_bib22","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.008_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2415.2415","article-title":"Inhibition of Akt\/mTOR signalling pathway induces cell cycle arrest and apoptosis in mantle cell lymphoma","volume":"106","author":"Peponi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.008_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2012.04.008_bib25","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2005.05630.x","article-title":"Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways","volume":"130","author":"Rizzatti","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2012.04.008_bib26","first-page":"8226","article-title":"The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival","volume":"63","author":"Martinez","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2012.04.008_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2006.01.021","article-title":"TORgeting oncogene addiction for cancer therapy","volume":"9","author":"Choo","year":"2006","journal-title":"Cancer Cell."},{"key":"10.1016\/j.beha.2012.04.008_bib28","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2005-11-026344","article-title":"Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells","volume":"110","author":"Kawamata","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.008_bib29","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.4161\/cc.7.18.6733","article-title":"GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma","volume":"7","author":"Dal Col","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.beha.2012.04.008_bib30","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1074\/jbc.M309999200","article-title":"AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression","volume":"279","author":"Gera","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2012.04.008_bib31","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.008_bib32","article-title":"Antiproliferative activity of RAD001 as a single-agent and combined with other agents in mantle cell lymphoma","author":"Haritunians","year":"2006","journal-title":"Am Assoc Can Res"},{"key":"10.1016\/j.beha.2012.04.008_bib33","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.2353\/ajpath.2006.051078","article-title":"Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma","volume":"169","author":"Peponi","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.beha.2012.04.008_bib34","first-page":"1433","article-title":"Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells","volume":"90","author":"Hipp","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2012.04.008_bib35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1172\/JCI28833","article-title":"Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma","volume":"117","author":"Amaravadi","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beha.2012.04.008_bib36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood-2011-04-346601","article-title":"Dual mTORC1\/mTORC2 inhibition\u00a0diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.008_bib37","doi-asserted-by":"crossref","unstructured":"Fernandez V, Salamero O, Espinet B, et\u00a0al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res; 70: 1408\u20131418.","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"10.1016\/j.beha.2012.04.008_bib38","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.008_bib39","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2012.04.008_bib40","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.008_bib41","first-page":"118","article-title":"Effect of prognostic risk classification on temsirolimus efficacy and safety outcomes in patients with relapsed\/refractory mantle cell lymphoma","author":"Hess","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.008_bib42","first-page":"116","article-title":"PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib","author":"O'Connor","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.008_bib43","first-page":"116","article-title":"A multi-center phase II study (SAKK 36\/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","author":"Renner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.008_bib44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2012.04.008_bib45","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.008_bib46","first-page":"118","article-title":"Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report on an ongoing phase I\/II trial","author":"Hess","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.008_bib47","first-page":"118","author":"Meadows","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.008_bib48","first-page":"118","article-title":"Phase I trial of a novel combination of an HDAC inhibitor (LBH589) and an mTOR inhibitor (RAD001) in lymphoid and plasma cell malignancies","author":"Kumar","year":"2011","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692612000357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692612000357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T19:45:54Z","timestamp":1594151154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692612000357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1521692612000357"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2012.04.008","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}